AA
DSGN icon

AlphaCentric Advisors’s Design Therapeutics DSGN Stock Holding History

AlphaCentric Advisors’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$226K Buy
21,231
+969
+5% +$9.8K 0.23% 134
2025
Q4 		$190K Buy
+20,262
New +$159K 0.19% 148

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AlphaCentric Advisors's DSGN Position: Q1 2026 in Review

AlphaCentric Advisors increased its Design Therapeutics (DSGN) stake by 4.8% in Q1 2026, buying an estimated $9.8K and bringing the position to 21,231 shares worth $226K. The position accounts for 0.23% of the portfolio, ranked #134.

AlphaCentric Advisors first reported a position in DSGN in Q4 2025 and has held it in 2 quarters since. 125 funds tracked by Wall St. Rank hold DSGN as of Q1 2026.

  • AlphaCentric Advisors held 21,231 shares of Design Therapeutics worth $226K as of Q1 2026.
  • AlphaCentric Advisors bought 969 Design Therapeutics shares in Q1 2026, an estimated $9.8K.
  • Design Therapeutics made up 0.23% of AlphaCentric Advisors's portfolio in Q1 2026, its #134 holding.
  • AlphaCentric Advisors first reported a position in Design Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 125 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2026.

Based on AlphaCentric Advisors's 13F filing for Q1 2026, filed 7 May 2026.